ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma

Chen, Jie; Li, Shuai; Huang, Zhexun; Cao, Congyuan; Wang, Anxun*; He, Qianting*南方医科大学; 中山大学; 1
Cancer Cell International2022-9-27DOI: 10.1186/s12935-022-02715-7
2被引8阅读
引用收藏
分享

摘要

Background N6-methyladenosine (m(6)A) is an abundant nucleotide modification in mRNA, but there were few studies on its role in cancer drug sensitivity and resistance. Anlotinib has been proved to have effective antitumor effects in oral squamous cell carcinoma (OSCC) in our previous study. Here, we sought to investigate the treatment target of anlotinib and the function and mechanisms of m(6)A modification in regulating anlotinib effect in OSCC. Methods Anlotinib treatment in a dose-dependent manner, western blotting, qRT-PCR and cell lost-of-function assays were used to study the treatment target of anlotinib in OSCC. RNA m(6)A dot blot assays, the m(6)A MeRIP-seq and MeRIP-qPCR, RNA and protein stability assays were used to explore the m(6)A modification of the treatment target of anlotinib. Cell lost-of-function assays after METTL3 depletion were conducted to investigate the effect of m(6)A modification level on the therapeutic effect of anlotinib in OSCC. Patient-derived tumor xenograft (PDX) models and immunohistochemistry staining were performed to study the relationship of METTL3 and antitumor sensitivity of anlotinib in vivo. Results Anlotinib targeted FGFR3 in the treatment of OSCC and inhibited tumor cell proliferation and promoted apoptosis by inactivating the FGFR3/AKT/mTOR signaling pathway. METTL3 was identified to target and modify FGFR3 m(6)A methylation and then decrease the stability of mRNA. METTL3 expression level was related to the anlotinib sensitivity in OSCC cells in vitro and METTL3 knockdown promoted anlotinib sensitivity of OSCC cells by inhibiting the FGFR3 expression. PDX models samples furthermore showed that METTL3 and FGFR3 levels were tightly correlated with the anlotinib efficacy in OSCC. Conclusions In summary, our work revealed that FGFR3 was served as the treatment target of anlotinib and METTL3-mediated FGFR3 m(6)A modification played a critical function in the anlotinib sensitivity in OSCC.

学科与关键词

关键词
OSCCAnlotinibMETTL3FGFR3TKIm(6)A methylation
相关
加载中…
  • METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1
    Ai, Yilong; Liu, Shiwei; Luo, Hailing; Wu, Siyuan; Wei, Haigang; Tang, Zhe; Li, Xia; Lv, Xiaozhi*; Zou, ChenJournal of Immunology Research, 2021, 2021: 6149558.被引 24
  • Mechanism of METTL14 and m6A modification of lncRNA MALAT1 in the proliferation of oral squamous cell carcinoma cells
    Li, Jinli; Momen-Heravi, Fatemeh*; Wu, Xun*; He, KailiOral Diseases, 2023, 29(5): 2012-2026.被引 8
  • Roles of m6A modification in oral cancer (Review)
    Liu, Huimin; Wang, Yinyu; Xue, Tianyi; Yang, Zhijing; Kan, Shaoning; Hao, Ming; Gao, Yang; Wang, Dongxu*; Liu, Weiwei*International Journal of Oncology, 2023, 62(1): 5.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Cell International
发表日期
2022-09-27
卷期
第 22 卷, 第 1 期
页码
295
DOI
10.1186/s12935-022-02715-7
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82173041, 82002871]

作者

  • C

    Chen, Jie (第一作者)

    1 · sun yat sen univ

  • L

    Li, Shuai

    1 · sun yat sen univ · guangxi med univ

查看全部 6 位作者收起作者
  • H

    Huang, Zhexun

    southern med univ

  • C

    Cao, Congyuan

    1 · sun yat sen univ

  • W

    Wang, Anxun (通讯)

    1 · sun yat sen univ

  • H

    He, Qianting (通讯)

    1 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417